Insight into mechanisms and receptor(s) involved in PBI-4050’s beneficial effect on kidney fibrosis and inflammation

PBI-4050 is a novel compound developed by ProMetic Life Sciences Inc. possessing anti-inflammatory and anti-fibrotic effects. PBI-4050 targets a family of cell receptor(s) expressed throughout the body, which are involved in diseases marred by fibrosis and inflammation. The first aim is designed to test PBI-4050’s efficacy preserving kidney function in a mouse model of advanced injury. The second aim is to generate genetically modified mice whereby PBI-4050’s targeted receptor(s) will be abolished and subject these to models of renal injury. We expect that genetic deletion of these receptors should mimic the beneficial effect of PBI-4050 treatment, while enhanced expression is thought to exacerbate disease progression. Data generated from these studies should provide a mechanistic proof-of-principle for PBI-4050 and reinforce its therapeutic potential.

Faculty Supervisor:

Christopher Kennedy

Student:

Partner:

ProMetic Life Sciences Inc

Discipline:

Life Sciences

Sector:

Manufacturing

University:

University of Ottawa

Program: